Hepatocellular Carcinoma Clinical Trials in Irvine, California

3 studies are recruiting for hepatocellular carcinoma in Irvine, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

    The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment of a type of liver cancer called hepatocellular carcinoma (HCC) that is either locally advanced (spread to nearby tissues) or has spread t…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California
    Locations
    54 in total
    Run by
    Pfizer

    See if you can join NCT07227012 on ClinicalTrials.gov

  2. A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

    This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tum…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California
    Locations
    62 in total
    Run by
    Seagen, a wholly owned subsidiary of Pfizer

    See if you can join NCT05208762 on ClinicalTrials.gov

  3. A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

    Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    City of Hope at Orange County Lennar Foundation Cancer Center /ID# 261669, Irvine, California
    Locations
    37 in total
    Run by
    AbbVie

    See if you can join NCT06109272 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.